Patents by Inventor John Reynders

John Reynders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20230416324
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: October 25, 2022
    Publication date: December 28, 2023
    Inventors: Stephen G. HOGE, William Joseph ISSA, Edward John MIRACCO, Jennifer NELSON, John REYNDERS, Matthew STANTON
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20190092828
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: July 30, 2018
    Publication date: March 28, 2019
    Inventors: Stephen G. HOGE, William Joseph ISSA, Edward John MIRACCO, Jennifer NELSON, John REYNDERS, Matthew STANTON
  • Alternative nucleic acid molecules containing reduced uracil content and uses thereof
    Patent number: 10072057
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 11, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20180009866
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 11, 2018
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton
  • Alternative nucleic acid molecules containing reduced uracil content and uses thereof
    Patent number: 9751925
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: September 5, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20160237134
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: December 4, 2015
    Publication date: August 18, 2016
    Inventors: Stephen G. HOGE, William Joseph ISSA, Ed MIRACCO, Jennifer NELSON, John REYNDERS, Matthew STANTON
  • Synchronized data-centric and document-centric knowledge management system for drug discovery and development
    Publication number: 20040249836
    Abstract: The system maintains both a document-centric and a data-centric representation of data gathered during the ingest stage. Data ingest may be by internal instrument data capture, external data capture and/or manual data capture. Data is managed in a query-able form; communication among data processing modules is effected using XML. The system allows data to be cast to and from a variety of different domain-specific representations, for consumption by a variety of different domain-specific analysis stages.
    Type: Application
    Filed: July 24, 2003
    Publication date: December 9, 2004
    Inventors: John Reynders, Scott Henderson